Trial · NCT02257567
Results by group986
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 986
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Arms G+H: (Phase II NF Cohorts): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin (Lyophilized) | Arm H (Phase II NF Cohort): Pola+BR in DLBCL | Post-Baseline Incidence of ADAs to Polatuzumab | 5.0 | percentage of participants | |
Phase II Randomized and NF Cohorts: Percentage of Participants With Complete Response (CR) at Primary Response Assessment (PRA) Based on Positron Emission Tomography (PET)-Computed Tomography (CT) Scan as Determined by Independent Review Committee (IRC) | Arm A (Phase II Randomization): Pola+BR in FL | 69.2 | 95% Confidence Interval 52.43 to 82.98 | percentage of participants | |
Phase II Randomized and NF Cohorts: Percentage of Participants With Complete Response (CR) at Primary Response Assessment (PRA) Based on Positron Emission Tomography (PET)-Computed Tomography (CT) Scan as Determined by Independent Review Committee (IRC) | Arm B (Phase II Randomization): BR in FL | 63.4 | 95% Confidence Interval 46.94 to 77.88 | percentage of participants | |
Phase II Randomized and NF Cohorts: Percentage of Participants With Complete Response (CR) at Primary Response Assessment (PRA) Based on Positron Emission Tomography (PET)-Computed Tomography (CT) Scan as Determined by Independent Review Committee (IRC) | Arm C (Phase II Randomization): Pola+BR in DLBCL | 42.5 | 95% Confidence Interval 27.04 to 59.11 | percentage of participants | |
Phase II Randomized and NF Cohorts: Percentage of Participants With Complete Response (CR) at Primary Response Assessment (PRA) Based on Positron Emission Tomography (PET)-Computed Tomography (CT) Scan as Determined by Independent Review Committee (IRC) | Arm D (Phase II Randomization): BR in DLBCL | 17.5 | 95% Confidence Interval 7.34 to 32.78 | percentage of participants | |
Phase II Randomized and NF Cohorts: Percentage of Participants With Complete Response (CR) at Primary Response Assessment (PRA) Based on Positron Emission Tomography (PET)-Computed Tomography (CT) Scan as Determined by Independent Review Committee (IRC) | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL | 39.6 | 95% Confidence Interval 30.25 to 49.59 | percentage of participants | |
| Arm H (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC | Arm H (Phase II NF Cohort): Pola+BR in DLBCL | 42.2 | 95% Confidence Interval 29.94 to 55.18 | percentage of participants | |
| Arm G (Phase II NF Cohort): Area Under Concentration-Time Curve (AUC) of Polatuzumab Vedotin (Lyophilized) | Arm G (Phase II NF Cohort): Pola+BR in DLBCL | acMMAE | 2880 | Geometric Coefficient of Variation 0.15 | ng*day/mL |
| Arm G (Phase II NF Cohort): Area Under Concentration-Time Curve (AUC) of Polatuzumab Vedotin (Lyophilized) | Arm G (Phase II NF Cohort): Pola+BR in DLBCL | MMAE | 21.6 | Geometric Coefficient of Variation 45 | ng*day/mL |
| Arm G (Phase II NF Cohort): Maximum Concentration (Cmax) of Polatuzumab Vedotin (Lyophilized) | Arm G (Phase II NF Cohort): Pola+BR in DLBCL | acMMAE | 724 | Geometric Coefficient of Variation 10 | nanograms per milliliters (ng/mL) |
| Arm G (Phase II NF Cohort): Maximum Concentration (Cmax) of Polatuzumab Vedotin (Lyophilized) | Arm G (Phase II NF Cohort): Pola+BR in DLBCL | MMAE | 2.01 | Geometric Coefficient of Variation 38 | nanograms per milliliters (ng/mL) |
| Phase II: Percentage of Participants With AEs | Arm A (Phase II Randomization): Pola+BR in FL | 100 | percentage of participants | ||
| Phase II: Percentage of Participants With AEs | Arm B (Phase II Randomization): BR in FL | 100 | percentage of participants | ||
| Phase II: Percentage of Participants With AEs | Arm C (Phase II Randomization): Pola+BR in DLBCL | 100 | percentage of participants | ||
| Phase II: Percentage of Participants With AEs | Arm D (Phase II Randomization): BR in DLBCL | 97.4 | percentage of participants | ||
| Phase II: Percentage of Participants With AEs | Arm E (Phase II Expansion): Pola+BG in FL | 100 | percentage of participants | ||
| Phase II: Percentage of Participants With AEs | Arm F (Phase II Expansion): Pola+BG in DLBCL | 100 | percentage of participants | ||
| Phase II: Percentage of Participants With AEs | Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL | 99.1 | percentage of participants | ||
| Arms A and C (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin | Arm A (Phase II Randomization): Pola+BR in FL | Baseline Prevalence of ADAs | 0 | percentage of participants | |
| Arms A and C (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin | Arm C (Phase II Randomization): Pola+BR in DLBCL | Baseline Prevalence of ADAs | 0 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02257567/results?page=2